The Europe Bronchodilators Market would witness market growth of 4.4% CAGR during the forecast period (2022-2028).
Corticosteroids commonly inhaled are added to beta-2 agonists to decrease pro-inflammatory agents and inflammation that further constrict airways. Beta-2 agonist class bronchodilators do not affect the underlying pathology of lung disease; they are only symptomatic treatments. Hence, adding inhaled corticosteroids to the regimen has been the mainstay of mild to moderate reversible lung diseases with or without long-acting beta-2 agonists. Anticholinergics are the final class of medicine that are considered bronchodilators.
This class's mechanism inhibits the effects of the parasympathetic nervous system medicated by the vagus nerve. A hyperactive parasympathetic nervous system causes airways and bronchial secretions to narrow. Medicines that inhibit the actions of the parasympathetic nervous system at the airway's low level will create a bronchodilatory effect.
These medicines include tiotropium bromide, which has a more prolonged effect of up to 24 hours, and ipratropium bromide, a short-acting medication that works for around 4 to 6 hours. Anticholinergics' primary function in the setting of chronic obstructive pulmonary disease. Patients with asthma can generally control their symptoms with a corticosteroid and a beta-2 agonist.
In England, smoking is one of the primary causes of health inequalities, with the harm focused on disadvantaged groups and communities. In 2019, around 13.9% of adults in England still smoked, approximately 6 million people. Smoking is one of the leading preventable causes of illness and premature death, responsible for around 74,600 deaths in England. In addition, one in 4 patients in a hospital bed is a smoker. The rising number of tobacco consumers will also increase the number of lung-based diseases and thereby surge the usage of medication like bronchodilators for their treatments, boosting the market growth in the region.
The Germany market dominated the Europe Bronchodilators Market by Country in 2021; thereby, achieving a market value of $1,671.7 million by 2028. The UK market is exhibiting a CAGR of 3.5% during (2022 - 2028). Additionally, The France market would experience a CAGR of 5.2% during (2022 - 2028).
Based on Drug Class, the market is segmented into Beta-Adrenergic, Xanthine Derivatives, and Anticholinergic. Based on Route of Administration, the market is segmented into Nasal (Inhalable), Oral, and Injectable. Based on Disease, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Bronchodilators Market will Hit $27 Billion by 2028, at a CAGR of 3.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.
By Drug Class
By Route of Administration
By Disease
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
